Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AMRNNASDAQ:DYNNASDAQ:MLYSNASDAQ:RAPT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$0.86-1.2%$1.00$0.65▼$1.49$352.89M1.982.04 million shs1.02 million shsDYNDyne Therapeutics$23.86+0.9%$25.99$6.40▼$30.27$2.06B0.952.02 million shs973,256 shsMLYSMineralys Therapeutics$11.29+5.0%$13.72$5.85▼$17.70$560.32M2.35161,311 shs102,466 shsRAPTRAPT Therapeutics$7.95+0.3%$11.01$6.86▼$27.35$276.66M0.471.19 million shs791,283 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-4.94%-14.53%+0.50%-16.97%-37.73%DYNDyne Therapeutics-4.71%-13.62%-14.06%+51.41%+124.81%MLYSMineralys Therapeutics-10.42%-18.00%-20.25%+22.58%-25.81%RAPTRAPT Therapeutics-1.37%-15.46%-8.22%-66.79%-58.89%Secret Bull Market Starts in This Unusual Sector (Ad)"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch. Click for my No. 1 investment, all free of charge, click here. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.9006 of 5 stars2.93.00.00.00.01.70.6DYNDyne Therapeutics3.4362 of 5 stars4.61.00.00.02.74.20.6MLYSMineralys Therapeutics1.9061 of 5 stars3.52.00.00.02.03.30.0RAPTRAPT Therapeutics4.298 of 5 stars4.34.00.03.61.31.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin1.75Reduce$1.0826.07% UpsideDYNDyne Therapeutics3.14Buy$37.4356.87% UpsideMLYSMineralys Therapeutics3.00Buy$33.50196.72% UpsideRAPTRAPT Therapeutics2.50Moderate Buy$25.67222.85% UpsideCurrent Analyst RatingsLatest MLYS, DYN, RAPT, and AMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral4/2/2024MLYSMineralys TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.003/27/2024RAPTRAPT TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.003/26/2024DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$47.003/26/2024MLYSMineralys TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/8/2024DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $31.003/6/2024DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.003/6/2024DYNDyne TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$35.00 ➝ $41.003/6/2024DYNDyne TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$27.00 ➝ $29.003/5/2024DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$44.00 ➝ $47.002/22/2024RAPTRAPT TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$61.00 ➝ $10.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$306.91M1.15N/AN/A$1.35 per share0.64DYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/AMLYSMineralys TherapeuticsN/AN/AN/AN/A$5.87 per shareN/ARAPTRAPT Therapeutics$1.53M180.82N/AN/A$4.27 per share1.86Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$59.11M-$0.14N/AN/AN/A-19.26%-10.47%-6.97%5/1/2024 (Confirmed)DYNDyne Therapeutics-$235.94M-$3.94N/AN/AN/AN/A-136.35%-103.67%5/9/2024 (Estimated)MLYSMineralys Therapeutics-$71.90M-$2.00N/AN/AN/AN/A-26.48%-25.52%5/20/2024 (Estimated)RAPTRAPT Therapeutics-$116.80M-$3.04N/AN/AN/AN/A-63.14%-55.48%5/9/2024 (Estimated)Latest MLYS, DYN, RAPT, and AMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2024N/AAMRNAmarin-$0.0350N/A+$0.0350N/AN/AN/A 3/21/2024Q4 2023MLYSMineralys Therapeutics-$0.85-$0.61+$0.24-$0.61N/AN/A 3/7/2024Q4 2023RAPTRAPT Therapeutics-$0.85-$0.80+$0.05-$0.80N/AN/A3/5/202412/31/2023DYNDyne Therapeutics-$0.92-$1.09-$0.17-$1.09N/AN/A2/29/2024Q4 2023AMRNAmarin-$0.05-$0.01+$0.04-$0.01$72.46 million$74.71 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ARAPTRAPT TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A2.801.80DYNDyne TherapeuticsN/A2.532.53MLYSMineralys TherapeuticsN/A23.7623.76RAPTRAPT TherapeuticsN/A7.417.41OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%DYNDyne Therapeutics96.68%MLYSMineralys Therapeutics84.46%RAPTRAPT Therapeutics99.09%Insider OwnershipCompanyInsider OwnershipAMRNAmarin1.96%DYNDyne Therapeutics20.77%MLYSMineralys TherapeuticsN/ARAPTRAPT Therapeutics6.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin275410.67 million402.62 millionOptionableDYNDyne Therapeutics14186.18 million68.28 millionOptionableMLYSMineralys Therapeutics2849.63 millionN/AOptionableRAPTRAPT Therapeutics13134.80 million32.50 millionOptionableMLYS, DYN, RAPT, and AMRN HeadlinesSourceHeadlineRAPT Therapeutics gets grant for inhibiting hematopoietic progenitor kinase 1 using pyrazole pyrimidine compoundspharmaceutical-technology.com - April 18 at 9:25 AMVertex buying Alpine for $4.9B for phase III-ready IgAN assetbioworld.com - April 12 at 8:27 AMHold Rating on RAPT Therapeutics Amid Promising Data and Regulatory Uncertaintiesmarkets.businessinsider.com - April 12 at 8:27 AMHC Wainwright Reiterates Neutral Rating for RAPT Therapeutics (NASDAQ:RAPT)americanbankingnews.com - April 12 at 3:22 AMRAPT reports positive phase 2 cancer trial resultsinvesting.com - April 11 at 1:51 AMMaintaining Hold Rating on RAPT Therapeutics Amidst Mixed Clinical Results and Regulatory Uncertaintymarkets.businessinsider.com - April 10 at 8:50 PMRAPT Therapeutics (NASDAQ:RAPT) Earns Neutral Rating from HC Wainwrightmarketbeat.com - April 10 at 8:17 AMRAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patientsglobenewswire.com - April 9 at 12:00 PMRapt Creative's glimpse of the past and nod to the futurebizcommunity.com - April 9 at 7:40 AM3 Biotech Stocks to Dump Before They Go to Zeroinvestorplace.com - April 9 at 6:31 AMRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Moderate Buy" from Analystsmarketbeat.com - April 4 at 2:31 AMShort Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Rises By 32.5%marketbeat.com - April 1 at 8:31 AMRAPT Therapeutics (NASDAQ:RAPT) Price Target Cut to $13.00marketbeat.com - March 27 at 10:59 AMFringe paceman Gannon savours WA's Shield three-peatillawarramercury.com.au - March 26 at 9:02 AMRAPT Apr 2024 10.000 putfinance.yahoo.com - March 16 at 8:39 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTprnewswire.com - March 11 at 6:06 PMLeap To Fame on his way to defending Grand Circuit titleharnesslink.com - March 11 at 8:04 AMHold Rating on RAPT Therapeutics Amid Clinical Trial Uncertainties and Financial Concernsmarkets.businessinsider.com - March 11 at 8:04 AMRAPT Oct 2024 5.000 callfinance.yahoo.com - March 8 at 12:09 AMRAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023investorplace.com - March 7 at 5:03 PMShould You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?zacks.com - March 7 at 9:41 AMRAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 7 at 8:00 AMRAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meetingglobenewswire.com - March 5 at 4:30 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTprnewswire.com - March 3 at 10:15 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAmarinNASDAQ:AMRNAmarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Dyne TherapeuticsNASDAQ:DYNDyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Mineralys TherapeuticsNASDAQ:MLYSMineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.RAPT TherapeuticsNASDAQ:RAPTRAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.